Blood Biomarkers for Screening of Alzheimer's Disease
Recruiting
- Conditions
- Alzheimer's DiseaseBlood Biomarkers
- Interventions
- Diagnostic Test: Blood biomarker
- Registration Number
- NCT06477484
- Lead Sponsor
- Peking University First Hospital
- Brief Summary
The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are:
* to identify core blood biomarker suitable for early screening of AD.
* to establish a comprehensive model for the early identification of AD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
- Age ≥ 50 years;
- AD (meets the 2011 NIA-AA AD diagnostic criteria), or MCI (meets the 2004 Peterson MCI diagnostic criteria), or cognitively normal subjects;
- Signed informed consent form.
Exclusion Criteria
- The presence of other disorders that can cause cognitive impairment;
- Unable to cooperate with the completion of cognitive assessment;
- Refusal to draw blood.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description different stages of individuals with Alzheimer's disease Blood biomarker -
- Primary Outcome Measures
Name Time Method Evaluate the diagnostic accuracy of blood biomarkers of Aβ42, Aβ40, Aβ42/Aβ40, P-Tau181, P-Tau217, GFAP and NfL. 2 years
- Secondary Outcome Measures
Name Time Method Evaluate the diagnostic accuracy of a comprehensive model combined with core blood biomarkers and clinical information. 2 years
Trial Locations
- Locations (1)
Peking University First Hospital
🇨🇳Beijing, Beijing, China